ReviewMolecular therapy. Nucleic acids2025
Nucleic acid therapeutics: Past, present, and future.
Review in Molecular therapy. Nucleic acids, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed.
- Design of liquid crystalline nanoparticles: Linking composition to membrane interactions and siRNA delivery.International journal of pharmaceutics: X · 2026Article
- Therapeutic resistance in cancer: lncRNAs as modulators and targets for cancer therapy.Genes & diseases · 2026Review
- A versatile strategy for oligonucleotide functionalization via on-support phosphitylation.Nature chemistry · 2026Article
- Article
- Recent Advances in Lipid Nanoparticle-Mediated Respiratory and Gastrointestinal Mucosal Delivery of Nucleic Acids.Bioengineering (Basel, Switzerland) · 2026Review
- Acyclic artificial nucleic acid substitution expands the safe design space of gapmer ASOs by preventing P54nrb mislocalization.NAR molecular medicine · 2026Article
- Investigating theBioconjugate chemistry · 2026Article
- Applications of micro/nano drug delivery systems in cancer pain management.Bioactive materials · 2026Review
- Lipid nanoparticles for nucleic acid delivery to osteoblasts and osteoblast-lineage cells: A systematic review.Bone reports · 2026Review
- CRISPR-Cas9 and next-generation gene editing strategies for therapeutic intervention of neurodegenerative pathways in Alzheimer's disease: a state-of-the-art review.Acta neurologica Belgica · 2026Review
- siRNA Delivery via Cross-Linked Gelatin Microparticles Enables Targeted Modulation of Osteogenic-Vascular Cross-Talk: An Advanced Human 3D in Vitro Test System for Therapeutic siRNA.Advanced healthcare materials · 2026Article
- Article
- The Role of Non-Coding RNAs in the Pathogenesis and Progression of Diabetic Kidney Disease.International journal of molecular sciences · 2026Review
- Nucleic-Acid-Based Strategies and Nanotechnology Applications for Targeted Therapy.Pharmaceutics · 2026Article
- Article
- Omega Nucleic Acids (ΩNA), Ultimate Nucleic Acids for Future Technology.Molecules (Basel, Switzerland) · 2026Review
- RNA therapeutic targeting of recalcitrant and rare cancers.Exploration of targeted anti-tumor therapy · 2026Review
- Beyond Small Molecules: Applying Fragment Molecular Orbital Sygnature Platform (FMO-SP) to Emerging Modalities.Methods in molecular biology (Clifton, N.J.) · 2026Article
- Emerging trends in nanomedicine: The role of RNAi-based therapies and onpattro's clinical journey.Iranian journal of basic medical sciences · 2026Review
- Olezarsen for the Treatment of Hypertriglyceridemia.Methods in molecular biology (Clifton, N.J.) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Nucleic acid therapeutics have become increasingly recognized in recent years for their capability to target both coding and non-coding sequences. Several types of nucleic acid modalities, including siRNA, mRNA, aptamer, along with antisense oligo, have been approved by regulatory bodies for therapeutic use. The field of nucleic acid therapeutics has been brought to the forefront by the rapid development of vaccines against COVID-19, followed by a number of approvals for clinical use including much anticipated CRISPR-Cas9. However, obstacles such as the difficulty of achieving efficient and targeted delivery to diseased sites remain. This review provides an overview of nucleic acid therapeutics and highlights substantial advancements, including critical engineering, conjugation, and delivery strategies, that are paving the way for their growing role in modern medicine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.